The COVID-19 outbreak that began in Wuhan, China in December 2019 was marked by an increase in the numb…
xMAP® Connect Virtual Conference – Inspiring Multiplexing Innovation
Luminex is proud to announce the xMAP® Connect Virtual Conference, hosted online this year by LabRoots. The go…
In Germany, Screening for COVID-19 with the ARIES® System
Clinical lab scientist describes his experience establishing a two-step diagnostic algorithm for COVID-19 Scie…
Luminex’s Flexible SARS-CoV-2 Assays Enable Both High-Throughput and Emergency Testing
Federal funding and FDA Emergency Use Authorization streamlined development and commercialization of these new…
Questions to Ask When Choosing a Multiplex Assay Kit
With the COVID‑19 pandemic in full swing, many researchers are looking to multiplex assays to evaluate w…
How Luminex Is Supporting Research Partners’ Pandemic Response
Licensed Technologies Group is finding new ways to boost partner programs Here at Luminex, we are working on a…
Considerations Regarding RNA Extraction Kits for SARS-CoV-2 Detection
The novel coronavirus disease (COVID-19) pandemic continues to trigger rapid development of molecular diagnost…
Webinar: Mouse Model Analysis Is Better with Multiplexing
Query hundreds of immunoassay targets, even with limited sample volume To make the most of immunology-focused …
How to Choose an Assay Development Platform
The Luminex Team knows assay development. Check out some tips from our experts below. If you need to design a …
The Faces of Luminex: Kurt Hoffacker, Chemistry R&D
Developing immunoassay technology and platforms takes innovation and hard work on a number of fronts—hardware,…